Phase 3 N=87 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Desmoid Tumors · Aggressive Fibromatosis
Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Phase 3 N=142 Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Desmoid Tumor · Aggressive Fibromatosis
Primary: Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause. — NA; 15.1 Months — p=< 0.001
Phase 2 N=9 A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Desmoid Tumor
Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63
Phase 2 N=70 Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
Desmoid Tumor
Primary: Percentage of Patients Failure Free at 2 Years Following Study Entry — 36 percentage of participants
Phase 2 N=18 Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Dermatofibrosarcoma Protuberans
Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…
Phase 2 N=140 Repurposing Anti-TNF for Treating Dupuytren's Disease
Dupuytren's Disease
Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)
Phase 3 N=221 An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Fibrodysplasia Ossificans Progressiva
Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)
N/A N=183 Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Phase 2 N=4 Sirolimus and Familial Adenomatous Polyposis (FAP)
Adenomatous Polyposis Coli
Primary: Change in Marked Polyp Size — 16; 4; 0 Size of marked polyps
Phase 3 N=171 Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Number of Subjects With Any FAP-related Event. — 18; 23; 22; 2 Participants — p=0.1210
Phase 2 N=63 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants
N/A N=44 Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Number of Polyps — 18.6; 22.6 Number of Polyps
Phase 2 N=176 Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Plantar Fibromatosis
Primary: Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score — -9.844; -8.417 score on a scale — p=0.274
Phase 2 N=48 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Phase 2 N=58 An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva
Primary: Parts A and B: Percentage of Flare-ups With No New Heterotopic Ossification (HO) at Week 12 — 64.3; 72.5 percentage of flare-ups
Phase 3 N=35 Collagenase in the Treatment of Dupuytrens Disease
Dupuytren's Disease
Primary: Primary Outcome Measure is Reduction of Flexion Contracture of the Primary Joint. — 91.3; 0 % Joints
Phase 2 N=9 Medical Treatment of "High-Risk" Neurofibromas
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Phase 2 N=35 A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Advanced Adult Hepatocellular Carcinoma · Advanced Fibrolamellar Carcinoma
Primary: Overall Response Rate — 1; 20; 10; 4 Participants
N/A N=274 A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas.
Sarcoma
Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…
N/A N=492 Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)
Gastro Intestinal Stromal Tumor
Primary: Time to Next Treatment (TNT) — 26.7 months
Phase 2 N=80 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
N/A N=150 Ploidy and Stroma in Early Rectal Cancer
Rectal Cancer
Primary: Correlation Between Ploidy Status With Local Recurrence of Cancer — 3; 31; 14; 92 Participants
Phase 4 N=53 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
Phase 2 N=17 Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Advanced Malignant Solid Neoplasm · Cholangiocarcinoma · Metastatic Malignant Solid Neoplasm
Primary: Overall Response Rate (ORR) — 13.3 percentage of participants
Phase 2 N=36 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
Phase 2 N=17 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Adult Fibrosarcoma · Adult Leiomyosarcoma · Adult Liposarcoma
Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…
Phase 2 N=14 A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma
Lipoma
Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline
N/A N=50 Effectiveness of Diacutaneous Fibrolysis in Painful Shoulder
Shoulder Pain
Primary: Change in Active Flexion Movement After Intervention Minus Baseline — 9.48; -1.92 Sexagesimal Degrees — p=<0.01